Cost Curve
everything drug pricing and policy, every day
Connect
And thanks to everyone who weighed in on the future of Cost Curve. With that feedback, I'm committed to making 2025 a banner year
And PBM reform seems to be dead. For now. Maybe. (I'm choosing to think that reform is merely pining for the fjords)
Plus Pfizer pulls back the curtain on what the IRA's Part D benefit design change will cost them next year: $1 billion
And I have a survey on the future direction of Cost Curve for you all. I'd be eternally grateful for your feedback.
And 2024 has seen an explosion in great curation and commentary around health policy, and I'm grateful for that
And IQVIA documents the gap between drug approvals in the U.S. and those in Europe
And pieces on how to make our system more value-driven, the fate of PBM reform, and what Oz may do with IRA
And ICER says that Vertex's non-opioid pain med looks like a fantastic deal
Plus an important update on how to think about the pharmacy-closure story from last week
And another set of guesses on which drugs will be next up for price controls
And Michigan is set to be the next 340B battleground. Could the Wolverine State learn from the experience of the Gopher State?
And a breathless Reuters story suggests that industry thinks IRA fixes are in play during Trump 2.0
